Relationship Between Chronic Spontaneous Urticaria and Fibromyalgia Syndrome

Yıl 2023, Cilt: 5 Sayı: 3, 638 - 43, 18.09.2023

Sevgi Kulaklı , Işıl Deniz Oğuz , İlker Fatih Sarı , Halil Öğüt

https://doi.org/10.37990/medr.1284145

Cited By: 1

Öz

Aim: Autoimmunity, peripheral nerve dysfunction, and neurogenic inflammation are common mechanisms in chronic spontaneous urticaria (CSU) and fibromyalgia syndrome (FMS). We aimed to detect the prevalence of FMS in patients with CSU and to determine whether this prevalence was affected by the severity of urticaria, and dermatology life quality.
Material and Methods: Fifty-three patients with CSU and 49 controls were enrolled in this prospective, controlled, cross-sectional study. The severity of CSU was assessed using Urticaria Activity Scores (UAS), and Dermatology Life Quality Index (DLQI) scores were recorded. The 2016 fibromyalgia diagnostic criteria were used for the diagnosis of FMS, and FMS-related functional disability was assessed using the Fibromyalgia Impact Questionnaire (FIQ).
Results: Fibromiyalgia prevalence and the FIQ scores were higher in the CSU group than in the control (p=0.033 and p=0.004, respectively). There was no statistically significant difference between the urticaria durations and UAS of CSU with and without FMS (p>0.05), but DLQI scores were statistically significantly higher in CSU with FMS (p=0.007). A statistically significant moderate positive correlation was present between DLQI and FIQ, Widespread Pain Index, and Symptom Severity Scale scores (r=0.500, r=0.408, r=0.469, r=0.507, respectively).
Conclusions: The prevalence of FMS and the disability due to FMS was increased in CSU. Furthermore, the FMS prevalence was not affected by the duration and severity of urticaria; however, it was associated with decreased quality of life.

Anahtar Kelimeler

fibromiyalgia syndrome, chronic urticaria, quality of life

Kaynakça

• 1. Kocatürk Göncü E, Aktan Ş, Atakan N, et al. The Turkish guideline for the diagnosis and management of urticaria-2016. Turkderm-Arch Turk Dermatol Venerology.2016;50:82-98.
• 2. Darlenski R, Kazandjieva J, Zuberbier T, Tsankov N. Chronic urticaria as a systemic disease. Clin Dermatol. 2014;32:420-3.
• 3. Huang Y, Xiao Y, Zhang X, et al. A meta-analysis of observational studies on the association of chronic urticaria with symptoms of depression and anxiety. Front Med (Lausanne). 2020;7:39.
• 4. Steinhoff M, Ständer S, Seeliger S, et al. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol. 2003;139:1479-88.
• 5. Choi JE, Di Nardo A. Skin neurogenic inflammation. Semin Immunopathol. 2018;40:249-59.
• 6. Moyano S, Kilstein JG, Alegre de Miguel C. New diagnostic criteria for fibromyalgia: here to stay?. Rheumatol Clin. 2015;11:210-4.
• 7. Van Houdenhove B, Kempke S, Luyten P. Psychiatric aspects of chronic fatigue syndrome and fibromyalgia. Curr Psychiatry Rep. 2010;12:208-14.
• 8. Thune PO. The prevalence of fibromyalgia among patients with psoriasis. Acta Derm Venereol. 2005;85:33-7.
• 9. Staud R. Are patients with systemic lupus erythematosus at increased risk for fibromyalgia?. Curr Rheumatol Rep. 2006;8:430-5.
• 10. Kim SH. Skin biopsy findings: implications for the pathophysiology of fibromyalgia. Med Hypotheses. 2007;69: 141-4.
• 11. Ang DC, Hilligoss J, Stump T. Mast cell stabilizer (ketotifen) in fibromyalgia: phase 1 randomized controlled clinical trial. Clin J Pain. 2015;31:836-42.
• 12. Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46:319-29.
• 13. Morgan M, McCreedy R, Simpson J. Dermatology quality of life scales- a measure of impact of skin diseases. Br J Dermatol.1997;136:202-6.
• 14. Burckhardt CS, Clark SRI, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18:728-33.
• 15. Torresani C, Bellafiore S, De Panfilis G. Chronic urticaria is usually associated with fibromyalgia syndrome. Acta Derm Venereol. 2009;89:389-92.
• 16. Mathkhor AJ, Mohammed JQ. Prevalence of fibromyalgia syndrome in chronic urticaria. World Family Medicine. 2020;18:102-6.
• 17. Gözübüyükoğulları A, Tabanlıoğlu Onan D, Allı N. Fibromylgia syndrome in chronic urticaria patients. Turkderm. 2014;48:215-8.
• 18. Koca TT, Nazik H, Mülayim MK, Öztürk P. The relation of chronic idiopathic urticaria with fibromyalgia, sleep disturbance and anxiety. J Contemp Med. 2019;9:151-5.
• 19. Yener M, Erturan I, Ceyhan AM, et al. The evaluation of prevalence of fibromyalgia in patients with chronic urticaria. Med Sci Monit. 2013;19:757-61.
• 20. Hapa A, Özdemir O, Ersoy Evans S, et al. Evaluation of the frequency of fibromyalgia in patients with chronic urticaria. Turkderm. 2012;46:202-5.
• 21. Borchers AT, Gershwin ME. Fibromyalgia: a critical and comprehensive review. Clin Rev Allergy Immunol. 2015;49:100-51.
• 22. Mäkelä M, Heliövaara M. Prevalence of primary fibromyalgia in the Finnish population. BMJ. 1991;303:216-9.
• 23. White KP, Speechley M, Harth M, Ostbye T. The London fibromyalgia epidemiology study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol. 1999;26:1570-6.
• 24. Bergman S. Psychosocial aspects of chronic widespread pain and fibromyalgia. Disabil Rehabil. 2005;27:675-83.